These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29665197)

  • 1. Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
    Shen G; Li S; Cui W; Liu S; Liu Q; Yang Y; Gross M; Li W
    J Thromb Haemost; 2018 Jun; 16(6):1164-1175. PubMed ID: 29665197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.
    Czogalla KJ; Liphardt K; Höning K; Hornung V; Biswas A; Watzka M; Oldenburg J
    Blood Adv; 2018 Mar; 2(6):691-702. PubMed ID: 29581108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.
    Rishavy MA; Hallgren KW; Wilson L; Singh S; Runge KW; Berkner KL
    Blood; 2018 Jun; 131(25):2826-2835. PubMed ID: 29592891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.
    Czogalla KJ; Biswas A; Wendeln AC; Westhofen P; Müller CR; Watzka M; Oldenburg J
    Blood; 2013 Oct; 122(15):2743-50. PubMed ID: 23982176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
    Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
    J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin.
    Rost S; Fregin A; Hünerberg M; Bevans CG; Müller CR; Oldenburg J
    Thromb Haemost; 2005 Oct; 94(4):780-6. PubMed ID: 16270630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues.
    Lacombe J; Ferron M
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30050002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition.
    Wu S; Chen X; Jin DY; Stafford DW; Pedersen LG; Tie JK
    Blood; 2018 Aug; 132(6):647-657. PubMed ID: 29743176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.
    Tie JK; Jin DY; Tie K; Stafford DW
    J Thromb Haemost; 2013 Aug; 11(8):1556-64. PubMed ID: 23710884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
    Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
    Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avian interspecific differences in VKOR activity and inhibition: Insights from amino acid sequence and mRNA expression ratio of VKORC1 and VKORC1L1.
    Nakayama SMM; Morita A; Ikenaka Y; Kawai YK; Watanabe KP; Ishii C; Mizukawa H; Yohannes YB; Saito K; Watanabe Y; Ito M; Ohsawa N; Ishizuka M
    Comp Biochem Physiol C Toxicol Pharmacol; 2020 Feb; 228():108635. PubMed ID: 31639498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.
    Müller E; Keller A; Fregin A; Müller CR; Rost S
    BMC Genet; 2014 Feb; 15():17. PubMed ID: 24491178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation.
    Rishavy MA; Hallgren KW; Wilson LA; Usubalieva A; Runge KW; Berkner KL
    J Biol Chem; 2013 Nov; 288(44):31556-66. PubMed ID: 23918929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.
    Van Horn WD
    Crit Rev Biochem Mol Biol; 2013; 48(4):357-72. PubMed ID: 23631591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
    Czogalla KJ; Biswas A; Höning K; Hornung V; Liphardt K; Watzka M; Oldenburg J
    Nat Struct Mol Biol; 2017 Jan; 24(1):77-85. PubMed ID: 27941861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting.
    Hilton JK; Van Horn WD
    Nat Struct Mol Biol; 2017 Jan; 24(1):5-6. PubMed ID: 28054569
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.
    Chen X; Jin DY; Stafford DW; Tie JK
    Blood; 2018 Nov; 132(18):1974-1984. PubMed ID: 30089628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer.
    Shen G; Cui W; Zhang H; Zhou F; Huang W; Liu Q; Yang Y; Li S; Bowman GR; Sadler JE; Gross ML; Li W
    Nat Struct Mol Biol; 2017 Jan; 24(1):69-76. PubMed ID: 27918545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Warfarin Inhibition Kinetics Requires Stabilization of Intramembrane Vitamin K Epoxide Reductases.
    Li S; Liu S; Yang Y; Li W
    J Mol Biol; 2020 Aug; 432(18):5197-5208. PubMed ID: 32445640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Investigation of the Vitamin K Epoxide Reductase (VKORC1) Binding Site with Vitamin K.
    Chatron N; Abi Khalil R; Benoit E; Lattard V
    Biochemistry; 2020 Apr; 59(13):1351-1360. PubMed ID: 32182040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.